EP1140086A1 - N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines - Google Patents

N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines

Info

Publication number
EP1140086A1
EP1140086A1 EP99964297A EP99964297A EP1140086A1 EP 1140086 A1 EP1140086 A1 EP 1140086A1 EP 99964297 A EP99964297 A EP 99964297A EP 99964297 A EP99964297 A EP 99964297A EP 1140086 A1 EP1140086 A1 EP 1140086A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
occurrence
substituted
cycloalkyl
chr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99964297A
Other languages
German (de)
English (en)
Other versions
EP1140086A4 (fr
Inventor
Soo S. Ko
George V. Delucca
John V. Duncia
Joseph B. Santella, Iii
Dean A. Wacker
Paul S. Watson
Jeffrey G. Varnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of EP1140086A1 publication Critical patent/EP1140086A1/fr
Publication of EP1140086A4 publication Critical patent/EP1140086A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • NPY Neuropeptide Y
  • A is lower alkylene and R 4 may be phenyl optionally substituted with halogen.
  • U.S. Pat. No. 5,668,151 discloses Neuropeptide Y (NPY) antagonists comprising 1, 4-dihydropyridines with a piperidinyl or tetrahydropyridinyl-containing moiety attached to the 3-position of the 4-phenyl ring:
  • Q is selected from CH 2 , CHR 5 , CHR 13 , CR 13 R 13 , and CR 5 R 13 ;
  • R 1 and R 2 are independently selected from H, C ⁇ _ 8 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r c 3 - 6 cycloalkyl, and a
  • R 2 and R 3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R a ;
  • R lla and R lla ' are selected from H, C ⁇ _ 6 alkyl, C 2 -8 alkenyl, C 2 -s alkynyl, a (CH 2 ) r -C3- ⁇ o carbocyclic residue substituted with 0-5 R lle , and a
  • R 15b is selected from C ⁇ _e alkyl, C 2 - 8 alkenyl, C 2 -8 alkynyl, a (CH 2 ) r -C 3 _ 6 carbocyclic residue substituted with 0-3 R 15e , and (CH 2 ) r ⁇ 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 15e ;
  • R 15d at each occurrence, is selected from C 2 _ 8 alkenyl, C _s alkynyl, C ⁇ _ 6 alkyl substituted with 0-3 R 15e , a (CH 2 )r-C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 15e , and a (CH ) r 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 15e ;
  • R 15e is selected from ⁇ -s alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, (CH ) r C 3 _ 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, OH, SH,
  • R 13d at each occurrence, is selected from H, C ⁇ _ 6 alkyl, and C 3 - 6 cycloalkyl;
  • R 16d is selected from C 1 - 6 alkyl and phenyl
  • R 16e at each occurrence, is selected from C ⁇ _ 6 alkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , OH, and (CH 2 ) r OCi- 5 alkyl; and
  • R 15e is selected from C - ⁇ alkyl, Cl,
  • the present invention provides novel compounds of formula (I) and pharmaceutically acceptable salt forms thereof, wherein the compound of formula I is selected from:
  • R 6d at each occurrence, is selected from H, C - 5 alkyl, and C 3 - 6 cycloalkyl;
  • R 11 and R 12 join to form C 3 - 7 cycloalkyl
  • J is selected from CH 2 and CHR 5 ;
  • L is selected from CH 2 and CHR 5 ;
  • R 15a and R 15a ' are selected from H, C ⁇ _g alkyl, C 3 _ 6 cycloalkyl, and (CH ) r phenyl substituted with 0-3 R 15e ;
  • R 15b at each occurrence, is selected from H, C ⁇ _ 6 alkyl,
  • R 15e is selected from C ⁇ _ 6 alkyl, Cl,
  • Z is selected from NR la , CHCN, CHN0 2 , and C(CN) 2 ;
  • R lla and R lla ' are selected from H, C _ 6 alkyl, C 2 - 8 alkenyl, C 2 -8 alkynyl, a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-5 R lle , and a (CH 2 )r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R lle ;
  • g is selected from 0, 1, 2, 3, and 4;
  • R 6 at each occurrence, is selected from C ⁇ _ 4 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, (CF 2 )rCF 3 , CN, (CH 2 ) r OH, (CH 2 ) r OR 6b , (CH 2 ) r C (0) R 6b ,
  • R 6c is selected from C ⁇ _ 6 alkyl, C 3 _g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ - 5 alkyl, and (CH 2 ) r NR 6d R 6d ;
  • R 11 is selected from H, C ⁇ _g alkyl, (CH 2 ) r C 3 -g cycloalkyl, (CH 2 ) q OH, (CH 2 ) q OR ll , (CH 2 ) q NR lla R lla ', (CH 2 ) r C (0) R llb , (CH 2 ) r C(0)NR lla R ll ', (CH 2 ) q NR lla C(0)R lla , C _ 6 haloalkyl, (CH 2 ) r phenyl with 0-2 R ll , (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 15 ;
  • the present invention provides novel compounds of formula (I) , wherein:
  • R 16 at each occurrence, is selected from C ⁇ _ ⁇ alkyl, (CH 2 ) r C 3 - 6 cycloalkyl, CF 3 , Cl, Br, I, F, (CH 2 ) r NR 16a R 16a ', N0 2 , CN, OH, (CH 2 ) r OR 16d ,
  • R 16f at each occurrence, is selected from H, and C ⁇ - 5 alkyl .
  • R 16f at each occurrence, is selected from H, and C ⁇ - 5 alkyl .
  • R 9 is selected from H, C ⁇ _ 6 alkyl, (CH 2 ) r C 3 -g cycloalkyl, F, Cl, CN, (CH 2 ) r OH, (CH 2 ) r OR 9d , (CH 2 ) r NR 9a R 9a ' , (CH 2 ) r OC(0)NHR 9 ⁇ (CH 2 ) r phenyl substituted with 0-5 R 9e , and a heterocyclic system substituted with 0-2 R 9e , wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
  • R 9a and R 9a ' are selected from H, C ⁇ _ 6 alkyl, C 3 _ 6 cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 9e ;
  • R 1 a and R 14 ' are selected from H, C _ 6 alkyl, C 3 _g cycloalkyl, and (CH 2 ) r Phenyl substituted with 0-3 R 14e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 15e ;
  • R 14 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 _ 6 cycloalkyl, CF 3 , Cl, Br, I, F,
  • R 14e at each occurrence, is selected from C ⁇ _g alkyl, Cl,
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, ; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0 ] bicyclodecane (decalin) , [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin) .
  • heterocycle or
  • Displacement of the SMe group with amines yields substituted guanidines 23 (see H. King and I. M. Tonkin J. Chem. Soc . 1946, 1063 and references therein) .
  • reaction of thiourea 21 with amines in the presence of triethanola ine and "lac sulfur" which facilitates the removal of H 2 S yields substituted guanidines 23 (K. Ramadas, Tet. Lett. 1996, 37, 5161 and references therein).
  • alcohol 55 or 58 may be tosylated, mesylated, triflated, or converted to a halogen by methods familiar to one skilled in the art to produce compound 59.
  • carbon homologs of 55 or 58 where OH can be (CH 2 ) r OH and it is also understood that these carbon homologs may have substituents on the methylene groups as well
  • a hydroxyl group may be converted to a bromide by CBr 4 and Ph 3 P (Takano, S. Heterocycles 1991, 32,
  • R 9 is either in its final form or in a suitable protected precursor form.
  • This electrophile can be a carbon-based electrophile, some examples being formaldehyde to introduce a CH 2 OH group, an aldehyde or a ketone which also introduces a one-carbon homologated alcohol, ethylene oxide (or other epoxides) which introduces a -CH 2 CH 2 OH group (a two-carbon homologated alcohol), an alkyl halide, etc., all of which can be later elaborated into R 9 .
  • It can also be an oxygen-based electrophile such as MCPBA, Davis' reagent (Davis, F. A. ; Haque, M.
  • amine 1 might have to be activated with Lewis acids in order to open the epoxide ring (Fujiwara, M. ; Imada, M.; Baba, A.; Matsuda, H. ; etrahedron Lett 1989, 30, 739; Caron, M. ; Sharpless, K. B.; J Org Chem 1985, 50, 1557) or 1 has to be deprotonated and used as a metal amide, for example the lithium amide (Gorzynski-Smith, J.; Synthesis 1984 (8), 629) or MgBr amide (Carre, M. C; Houmounou, J. P.; Caubere, P.; Tetrahedron Lett 1985, 26, 3107) or aluminum amide (Overman, L. E.; Flippin, L. A.; Tetrahedron Lett 1981, 22, 195).
  • Lewis acids for example the lithium amide (Gorzynski-Smith, J.; Synthesis 1984 (8), 629) or M

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des modulateurs de CCR3, de formule (I), ou leurs sels pharmaceutiquement acceptables, utiles dans la prévention de l'asthme et d'autres maladies allergiques.
EP99964297A 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines Withdrawn EP1140086A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11271798P 1998-12-18 1998-12-18
US112717P 1998-12-18
US16124399P 1999-10-22 1999-10-22
US161243P 1999-10-22
PCT/US1999/030332 WO2000035451A1 (fr) 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines

Publications (2)

Publication Number Publication Date
EP1140086A1 true EP1140086A1 (fr) 2001-10-10
EP1140086A4 EP1140086A4 (fr) 2002-04-03

Family

ID=26810265

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99964297A Withdrawn EP1140086A4 (fr) 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines

Country Status (4)

Country Link
EP (1) EP1140086A4 (fr)
AU (1) AU2057200A (fr)
CA (1) CA2350730A1 (fr)
WO (1) WO2000035451A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DK1179341T3 (da) 1999-05-18 2006-03-27 Teijin Ltd Lægemidler eller forebyggende midler mod sygdomme der er associeret med chemokiner
KR100667645B1 (ko) 1999-08-04 2007-02-28 데이진 가부시키가이샤 환상 아민 ｃｃｒ3 길항제
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US6784200B2 (en) 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
JP2003512349A (ja) 1999-10-15 2003-04-02 デュポン ファーマシューティカルズ カンパニー ケモカイン受容体活性のモジュレーターとしてのベンジルシクロアルキルアミン
EP1220840A2 (fr) 1999-10-15 2002-07-10 Bristol-Myers Squibb Pharma Company Amines bicyliques et tricycliques en tant que modulateurs de l'activite du recepteur de chemokine
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AU2001268607A1 (en) 2000-06-21 2002-01-02 Bristol-Myers Squibb Company Piperidine amides as modulators of chemokine receptor activity
US6627629B2 (en) 2000-06-30 2003-09-30 Bristol-Myers Squibb Pharma N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity
AR035205A1 (es) 2000-09-29 2004-05-05 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
ATE374198T1 (de) 2000-12-19 2007-10-15 Hoffmann La Roche Substituierte pyrrolidine als ccr-3- rezeptorantagonisten
US20040053936A1 (en) * 2000-12-22 2004-03-18 Yohko Akiyama Medicinal composition for oral use
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
AR035230A1 (es) 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US6977265B2 (en) 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
AU2002352122A1 (en) 2001-11-30 2003-06-10 F. Hoffmann-La Roche Ag Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
DE60222015T2 (de) 2001-11-30 2008-06-05 F. Hoffmann-La Roche Ag Ccr-3-rezeptorantagonisten vii
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EA009296B1 (ru) 2003-04-24 2007-12-28 Инсайт Корпорейшн Производные азаспироалканов в качестве ингибиторов металлопротеаз
US7351720B2 (en) * 2003-06-12 2008-04-01 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US8143404B2 (en) 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
EP1889622A4 (fr) 2005-05-31 2009-12-23 Ono Pharmaceutical Co Compose de spiropiperidine et son utilisation medicinale
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
DK1942108T3 (da) 2005-10-28 2013-12-09 Ono Pharmaceutical Co Forbindelse indeholdende basisk gruppe samt anvendelse deraf
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
WO2007132846A1 (fr) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Composé ayant un groupe acide qui peut être protégé et utilisation dudit composé
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
WO2010129351A1 (fr) 2009-04-28 2010-11-11 Schepens Eye Research Institute Procédé pour identifier et pour traiter une dégénérescence maculaire liée à l'âge

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001134A (en) * 1989-01-05 1991-03-19 Lipha, Lyonnaise Industrielle Pharmaceutique Piperidines, processes of preparation and medications containing them
EP0479601A2 (fr) * 1990-10-05 1992-04-08 Ajinomoto Co., Inc. Dérivés de la pipéridine et leur application comme agents anti-arrhythmiques
EP0747357A2 (fr) * 1995-06-07 1996-12-11 Bristol-Myers Squibb Company Dihydropyridines comme antagonistes de NPY: dérivés de pipéridine
EP0903349A2 (fr) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag Antagonistes du récepteur CCR-3
WO2000029377A1 (fr) * 1998-11-17 2000-05-25 F. Hoffmann-La Roche Ag Antagonistes iii du recepteur 4-aroyl-piperidin-ccr-3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988294A (en) * 1974-03-11 1976-10-26 R. T. Vanderbilt Company, Inc. Surface coating compositions containing antimicrobic ureas
JP2826826B2 (ja) * 1988-04-11 1998-11-18 日本ケミファ株式会社 アルキレンジアミン誘導体
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
DK60893D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Piperidinderivater, deres fremstilling og anvendelse
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001134A (en) * 1989-01-05 1991-03-19 Lipha, Lyonnaise Industrielle Pharmaceutique Piperidines, processes of preparation and medications containing them
EP0479601A2 (fr) * 1990-10-05 1992-04-08 Ajinomoto Co., Inc. Dérivés de la pipéridine et leur application comme agents anti-arrhythmiques
EP0747357A2 (fr) * 1995-06-07 1996-12-11 Bristol-Myers Squibb Company Dihydropyridines comme antagonistes de NPY: dérivés de pipéridine
EP0903349A2 (fr) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag Antagonistes du récepteur CCR-3
WO2000029377A1 (fr) * 1998-11-17 2000-05-25 F. Hoffmann-La Roche Ag Antagonistes iii du recepteur 4-aroyl-piperidin-ccr-3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0035451A1 *

Also Published As

Publication number Publication date
EP1140086A4 (fr) 2002-04-03
WO2000035451A1 (fr) 2000-06-22
AU2057200A (en) 2000-07-03
CA2350730A1 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
EP1158980B1 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6780857B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6444686B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140086A1 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6525069B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035449A1 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6605623B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098270A2 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
EP1363881A2 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
US6897234B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2001271359A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA01006148A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20010605;LV PAYMENT 20010605;MK;RO PAYMENT 20010605;SI PAYMENT 20010605

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VARNES, JEFFREY G.

Inventor name: WATSON, PAUL, S.

Inventor name: WACKER, DEAN, A.

Inventor name: SANTELLA, JOSEPH, B., III

Inventor name: DUNCIA, JOHN, V.

Inventor name: DELUCCA, GEORGE, V.

Inventor name: KO, SOO, S.

A4 Supplementary search report drawn up and despatched

Effective date: 20020219

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A, 7C 07D 211/32 B, 7C 07D 211/52 B, 7C 07D 211/58 B, 7C 07D 211/62 B, 7C 07D 211/66 B, 7C 07D 211/76 B, 7C 07D 221/20 B, 7C 07D 401/04 B, 7C 07D 211/18 B, 7C 07D 211/20 B, 7C 07D 211/26 B, 7C 07D 401/12 B

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRISTOL-MYERS SQUIBB PHARMA COMPANY

17Q First examination report despatched

Effective date: 20030616

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050405